Psomagen, Inc. (950200.KQ)
KOSDAQ · KRW · Healthcare · Diagnostics & Research
₩2,835 (+0.35%) as of
Key statistics
- Market cap
- 54.53B
- Dividend yield
- 0.00%
- 52-week range
- 0.00 – 4,690.00
- Beta
- -0.20
- Revenue (TTM)
- 60.7B
- Profit margin
- -2.62%
About Psomagen, Inc.
Psomagen, Inc. engages in the provision omics solutions and contract laboratory services. The company's research services includes genomics, a study of gene sequence and expression; epigenomics, a study of epigenetic changes, such as chromatin assembly, histone modification, and DNA-protein interaction in a cell; single-cell analysis, research in suspensions, biological fluids, tissues, or cell populations; metagenomics, a study of genetic material from microorganisms in heterogeneous samples; transcriptomics, a study of RNA and its expression through sequencing, used to analyze the impact of gene expression on the biology of an organism; and proteomics, a study of all the expressed proteins in an organism (proteome). It also offers Bioinformatics, a software tool and pipeline that helps scientists in analyzing data; and provides clinical genetic testing, whole-genome, whole-exome, and sanger sequencing services. The company was formerly known as Macrogen Corp. and changed its name to Psomagen, Inc. in April 2019. Psomagen, Inc. was incorporated in 2004 and is headquartered in Wilmington, Delaware. Psomagen, Inc. is a subsidiary of Macrogen, Inc.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Wilmington, DE, United States
- Employees
- 87
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.